Literature DB >> 30725173

Novel methods in adrenal research: a metabolomics approach.

Thomas G Papathomas1,2, Na Sun2, Vasileios Chortis1,3, Angela E Taylor1,3, Wiebke Arlt1,3, Susan Richter4,5, Graeme Eisenhofer4,5,6, Gerard Ruiz-Babot6,7,8, Leonardo Guasti8, Axel Karl Walch9.   

Abstract

Metabolic alterations have implications in a spectrum of tissue functions and disease. Aided by novel molecular biological and computational tools, our understanding of physiological and pathological processes underpinning endocrine and endocrine-related disease has significantly expanded over the last decade. Herein, we focus on novel metabolomics-related methodologies in adrenal research: in situ metabolomics by mass spectrometry imaging, steroid metabolomics by gas and liquid chromatography-mass spectrometry, energy pathway metabologenomics by liquid chromatography-mass spectrometry-based metabolomics of Krebs cycle intermediates, and cellular reprogramming to generate functional steroidogenic cells and hence to modulate the steroid metabolome. All four techniques to assess and/or modulate the metabolome in biological systems provide tremendous opportunities to manage neoplastic and non-neoplastic disease of the adrenal glands in the era of precision medicine. In this context, we discuss emerging clinical applications and/or promising metabolic-driven research towards diagnostic, prognostic, predictive and therapeutic biomarkers in tumours arising from the adrenal gland and extra-adrenal paraganglia as well as modern approaches to delineate and reprogram adrenal metabolism.

Entities:  

Keywords:  Adrenal glands; Cellular reprogramming; In situ metabolomics; Metabologenomics; Steroid metabolomics

Mesh:

Year:  2019        PMID: 30725173     DOI: 10.1007/s00418-019-01772-w

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  130 in total

1.  Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome.

Authors:  S Ulick; J Z Wang; J D Blumenfeld; T G Pickering
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

2.  Premature mortality in patients with Addison's disease: a population-based study.

Authors:  Ragnhildur Bergthorsdottir; Maria Leonsson-Zachrisson; Anders Odén; Gudmundur Johannsson
Journal:  J Clin Endocrinol Metab       Date:  2006-09-12       Impact factor: 5.958

3.  Defective ring A reduction of cortisol as the major metabolic error in the syndrome of apparent mineralocorticoid excess.

Authors:  S Ulick; R Tedde; J Z Wang
Journal:  J Clin Endocrinol Metab       Date:  1992-03       Impact factor: 5.958

4.  Prevalence and characteristics of the metabolic syndrome in primary aldosteronism.

Authors:  Francesco Fallo; Franco Veglio; Chiara Bertello; Nicoletta Sonino; Paolo Della Mea; Mario Ermani; Franco Rabbia; Giovanni Federspil; Paolo Mulatero
Journal:  J Clin Endocrinol Metab       Date:  2005-11-15       Impact factor: 5.958

5.  Subjective health status in Norwegian patients with Addison's disease.

Authors:  Kristian Løvås; Jon Håvard Loge; Eystein S Husebye
Journal:  Clin Endocrinol (Oxf)       Date:  2002-05       Impact factor: 3.478

Review 6.  Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family.

Authors:  Jacques Simard; Marie-Louise Ricketts; Sébastien Gingras; Penny Soucy; F Alex Feltus; Michael H Melner
Journal:  Endocr Rev       Date:  2005-01-04       Impact factor: 19.871

7.  The diagnosis of congenital adrenal hyperplasia in the newborn by gas chromatography/mass spectrometry analysis of random urine specimens.

Authors:  Michael P Caulfield; Thomas Lynn; Michael E Gottschalk; Kenneth L Jones; Norman F Taylor; Ewa M Malunowicz; Cedric H L Shackleton; Richard E Reitz; Delbert A Fisher
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

8.  Metabolic evidence for impaired 17alpha-hydroxylase activity in a kindred bearing the E305G mutation for isolate 17,20-lyase activity.

Authors:  Dov Tiosano; Carlos Knopf; Ilana Koren; Nurit Levanon; Michaela F Hartmann; Ze'ev Hochberg; Stefan A Wudy
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

9.  Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome.

Authors:  Christa E Flück; Toshihro Tajima; Amit V Pandey; Wiebke Arlt; Kouji Okuhara; Charles F Verge; Ethylin Wang Jabs; Berenice B Mendonça; Kenji Fujieda; Walter L Miller
Journal:  Nat Genet       Date:  2004-02-01       Impact factor: 38.330

10.  Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study.

Authors:  Wiebke Arlt; Elizabeth A Walker; Nicole Draper; Hannah E Ivison; Jon P Ride; Fabian Hammer; Susan M Chalder; Maria Borucka-Mankiewicz; Berthold P Hauffa; Ewa M Malunowicz; Paul M Stewart; Cedric H L Shackleton
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

View more
  5 in total

Review 1.  What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?

Authors:  Thomas G Papathomas; Diederik P D Suurd; Alfred K Lam; Ronald R de Krijger; Karel Pacak; Arthur S Tischler; Menno R Vriens
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

2.  In focus in HCB.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2022-05       Impact factor: 4.304

Review 3.  The Potential Role of Aldosterone-Producing Cell Clusters in Adrenal Disease.

Authors:  Jung Soo Lim; William E Rainey
Journal:  Horm Metab Res       Date:  2020-03-30       Impact factor: 2.936

Review 4.  The Role of Biomarkers in Adrenocortical Carcinoma: A Review of Current Evidence and Future Perspectives.

Authors:  Maja Mizdrak; Tina Tičinović Kurir; Joško Božić
Journal:  Biomedicines       Date:  2021-02-10

Review 5.  Adrenal Incidentaloma.

Authors:  Mark Sherlock; Andrew Scarsbrook; Afroze Abbas; Sheila Fraser; Padiporn Limumpornpetch; Rosemary Dineen; Paul M Stewart
Journal:  Endocr Rev       Date:  2020-12-01       Impact factor: 19.871

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.